Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
9.50
+0.68 (7.71%)
At close: May 12, 2025, 4:00 PM
9.50
0.00 (0.00%)
After-hours: May 12, 2025, 6:57 PM EDT
Upstream Bio Revenue
Upstream Bio had revenue of $566.00K in the quarter ending March 31, 2025, with 25.78% growth. This brings the company's revenue in the last twelve months to $2.30M, down -2.94% year-over-year. In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%.
Revenue (ttm)
$2.30M
Revenue Growth
-2.94%
P/S Ratio
108.98
Revenue / Employee
$44,154
Employees
52
Market Cap
511.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
Dec 31, 2022 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 6 days ago - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewsWire
- 25 days ago - Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha
- 6 weeks ago - 3 Dividend Giants To Buy As Tariffs Hit Stocks - Benzinga
- 2 months ago - Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 5 months ago - Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation - Seeking Alpha
- 5 months ago - Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewsWire
- 6 months ago - Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga